Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
A Transcriptomic and Connectomic Model for Neural Atrophies Induced by alpha-synuclein and Reversed by PU-AD
FY 2023-24
Summary
Aggregates of the misfolded alpha-synuclein (aSyn) protein are markers of regional brain cell loss in Parkinson’s disease (PD). aSyn aggregates are transmitted from infected neurons to connected neurons, allowing network transmission models from epidemiology to model how aSyn causes neurodegeneration. One such epidemic model is the Susceptible-Infected-Removed (SIR) model, which views each node in the network as uninfected, contagious, or inactive based on infection and clearance probabilities of a disease-causing agent. When using the SIR model to predict structural atrophies in PD, the “agent” is aSyn and the “network” and “nodes” in the brain are defined from structural MRI scans. Past work has predicted brain volume loss in PD at each node by assigning the probability of aSyn “infection” and “clearance” to the local expression patterns of two genes that produce and degrade aSyn, respectively. However, aSyn dynamics are more complex than single-gene pathways. We thus seek to enhance the accuracy and biological validity of the SIR model by expanding the genetic inputs used to model aSyn transmission and clearance. We will use gene expression and MRI data from mice expressing the human version of aSyn and injected with more aSyn in a defined region, allowing us to predict which genes correspond to rapid structural changes from a known “epicenter” in our network model. In doing so, we hope to screen for the genes that most strongly explain how aSyn drives brain structural changes in PD. After finding these genes, we can repeat our SIR analysis on drug trial data using the PU-AD drug in mice to see if any of the genes that drive PD progression are also involved in rescuing PD progression, making these genes ideal targets for pharmacological interventions.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
506389
Name
Nathan Vikram
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
A Transcriptomic and Connectomic Model for Neural Atrophies Induced by alpha-synuclein and Reversed by PU-AD
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Alpha-Synuclein; Connectomics; Diffusion Weighted Mri; Drug Trial Effects; Network Neuroscience Modelling; Neurodegeneration; Parkinson'S Disease; Sir Agent-Based Model; Structural Mri; Transcriptomics
Abstract
Aggregates of the misfolded alpha-synuclein (aSyn) protein are markers of regional brain cell loss in Parkinson’s disease (PD). aSyn aggregates are transmitted from infected neurons to connected neurons, allowing network transmission models from epidemiology to model how aSyn causes neurodegeneration. One such epidemic model is the Susceptible-Infected-Removed (SIR) model, which views each node in the network as uninfected, contagious, or inactive based on infection and clearance probabilities of a disease-causing agent. When using the SIR model to predict structural atrophies in PD, the “agent” is aSyn and the “network” and “nodes” in the brain are defined from structural MRI scans. Past work has predicted brain volume loss in PD at each node by assigning the probability of aSyn “infection” and “clearance” to the local expression patterns of two genes that produce and degrade aSyn, respectively. However, aSyn dynamics are more complex than single-gene pathways. We thus seek to enhance the accuracy and biological validity of the SIR model by expanding the genetic inputs used to model aSyn transmission and clearance. We will use gene expression and MRI data from mice expressing the human version of aSyn and injected with more aSyn in a defined region, allowing us to predict which genes correspond to rapid structural changes from a known “epicenter” in our network model. In doing so, we hope to screen for the genes that most strongly explain how aSyn drives brain structural changes in PD. After finding these genes, we can repeat our SIR analysis on drug trial data using the PU-AD drug in mice to see if any of the genes that drive PD progression are also involved in rescuing PD progression, making these genes ideal targets for pharmacological interventions.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Nathan, Vikram
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~